CancerDrs

Prostate Cancer clinical trials in Illinois

40 actively recruiting prostate cancer trials at 53 sites across Illinois.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full prostate cancer transparency page →

Phase 3 Recruiting Network

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Illinois:
  • University of Illinois — Chicago, Illinois
  • Elmhurst Memorial Hospital — Elmhurst, Illinois
  • Edward Hospital/Cancer Center — Naperville, Illinois
  • Edward Hospital/Cancer Center?Plainfield — Plainfield, Illinois
  • Memorial Hospital East — Shiloh, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in Illinois:
  • Alton Memorial Hospital — Alton, Illinois
  • OSF Saint Anthony's Health Center — Alton, Illinois
  • Rush-Copley Medical Center — Aurora, Illinois
  • Illinois CancerCare-Bloomington — Bloomington, Illinois
  • Illinois CancerCare-Canton — Canton, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Illinois:
  • Rush - Copley Medical Center — Aurora, Illinois
  • Illinois CancerCare-Bloomington — Bloomington, Illinois
  • Illinois CancerCare-Canton — Canton, Illinois
  • Illinois CancerCare-Carthage — Carthage, Illinois
  • Northwestern University — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07200830
Sites in Illinois:
  • Northwestern University — Chicago, Illinois
  • Cancer Care Specialists of Illinois - Decatur — Decatur, Illinois
  • Decatur Memorial Hospital — Decatur, Illinois
  • Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois
  • Northwestern Medicine Cancer Center Delnor — Geneva, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRP…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in Illinois:
  • Edward-Elmhurst Healthcare, Elmhurst Hospital-Nancy W. Knowles Cancer Center ( Site 0074) — Elmhurst, Illinois
  • Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center ( Site 0075) — Naperville, Illinois
  • Illinois Cancer Care ( Site 0104) — Peoria, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.

Sponsor: Pfizer
NCT ID: NCT06629779
Sites in Illinois:
  • Blessing Hospital — Quincy, Illinois
  • Blessing Physician Services — Quincy, Illinois
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in Illinois:
  • University of Chicago — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicine…

Sponsor: BioNTech SE
NCT ID: NCT07365995
Sites in Illinois:
  • Illinois Cancer Specialists — Niles, Illinois
  • Illinois CancerCare PC — Peoria, Illinois
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Federal

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…

Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in Illinois:
  • Edward Hines Jr. VA Hospital, Hines, IL — Hines, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

1. Personalize treatment for prostate cancer based on how aggressive the disease is and 2. Learn if apalutamide-based treatment can help to reduce fatigue and other side effects of treatment in participants who are being treated with radia…

Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT06274047
Sites in Illinois:
  • Rush MD Anderson — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing co…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05806515
Sites in Illinois:
  • NorthShore University HealthSystem-Evanston Hospital — Evanston, Illinois
  • NorthShore University HealthSystem-Glenbrook Hospital — Glenview, Illinois
  • NorthShore University HealthSystem-Highland Park Hospital — Highland Park, Illinois
  • North Shore Medical Center — Skokie, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in comb…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in Illinois:
  • University of Chicago Medical Center — Chicago, Illinois
  • Loyola University Medical Center — Maywood, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…

Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Illinois:
  • University of Chicago Medical Center — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carc…

Sponsor: Daiichi Sankyo
NCT ID: NCT06172478
Sites in Illinois:
  • University of Illinois Cancer Center — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

This phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation that has spread to other places in the body (metastatic). Neuroendocrine differentiation refe…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05691465
Sites in Illinois:
  • Northwestern University — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are ano…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07005154
Sites in Illinois:
  • Associated Urological Specialists — Chicago Ridge, Illinois
  • NorthShore University HealthSystem — Evanston, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

The purpose of this study is to learn about how an investigational drug intervention completed before doing prostate surgery (specifically, radical prostatectomy with lymph node dissection) may help in treatment of high risk localized pros…

Sponsor: VA Office of Research and Development
NCT ID: NCT05593497
Sites in Illinois:
  • Jesse Brown VA Medical Center, Chicago, IL — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

This phase II trial compares the effect of FDG-positron emission tomography (PET)-guided metastasis directed radiation therapy (MDRT) in combination with standard treatments to standard treatments alone in treating patients with prostate c…

Sponsor: Northwestern University
NCT ID: NCT06244004
Sites in Illinois:
  • Northwestern University — Chicago, Illinois
  • Northwestern Medicine: Kishwaukee — DeKalb, Illinois
  • Northwestern Medicine: Delnor — Geneva, Illinois
  • Northwestern University Oak Brook IL453 — Oak Brook, Illinois
  • Northwestern Medicine Orland Park — Orland Park, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

This trial tests if the combination of comprehensive metastasis directed therapy delivered by a precision form of external beam radiotherapy (stereotactic ablative radiotherapy), combined with PSMA targeted radiopharmaceutical therapy and …

Sponsor: VA Office of Research and Development
NCT ID: NCT06084338
Sites in Illinois:
  • Edward Hines Jr. VA Hospital, Hines, IL — Hines, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for indiv…

Sponsor: University of Chicago
NCT ID: NCT05726292
Sites in Illinois:
  • University of Chicago Comprehensive Cancer Center — Chicago, Illinois
  • Endeavor Health — Evanston, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

The goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remove their prostate cancer. It will also learn about the safety of FK-PC101. The m…

Sponsor: Cellvax Therapeutics Inc
NCT ID: NCT06636682
Sites in Illinois:
  • University of Chicago Medicine, High-Risk and Advanced Prostate Cancer Clinic — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation

The purpose of this research is to gather information on the safety and effectiveness of combining focal prostate ablation therapy ((aka Focal Therapy, a surgical procedure) and androgen deprivation therapy (hormone therapy).

Sponsor: University of Chicago
NCT ID: NCT05790213
Sites in Illinois:
  • UChicago Medicine Comprehensive Cancer Center — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

This phase II trial tests how well relugolix and enzalutamide, in combination with radiation therapy, works in treating patients with very high risk prostate cancer. Relugolix is a form of androgen deprivation therapy. It prevents the rele…

Sponsor: Sean Sachdev
NCT ID: NCT06499870
Sites in Illinois:
  • Northwestern University — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

GU-01: Glycyrrhizin in Prostate Cancer

This is a pilot, randomized, window-of-opportunity treatment trial in which participants with previously untreated prostate cancer (PCa) who are candidates for surgery (radical prostatectomy)

Sponsor: University of Illinois at Chicago
NCT ID: NCT06378346
Sites in Illinois:
  • University of Illinois — Chicago, Illinois
View on ClinicalTrials.gov →

Showing 25 of 40 trials with sites in Illinois. See all prostate cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19